REPAGLINIDA STADA 1 mg TABLETS

2. What you need to know before taking Repaglinida Stada

Do not take Repaglinida Stada:

• If you are allergic to repaglinide or any of the other components of this medication (listed in section 6).

• If you have type 1 diabetes(insulin-dependent diabetes)

• If your body's acid level has increased (diabetic ketoacidosis)
• If you have severe liver disease
• If you are taking gemfibrozil(a medication that lowers blood fat levels).

If any of the above applies to you, tell your doctorand do not take Repaglinida Stada.

Warnings and precautions

Consult your doctor or pharmacist before starting to take Repaglinida Stada if:

• You have liver problems. Repaglinida Stada is not recommended for patients with moderate liver disease. Repaglinida Stada should not be taken if you have severe liver disease (see Do not take Repaglinida Stada).

• If you have kidney problems. Repaglinida Stada should be taken with caution.

• If you are going to undergo major surgeryor have recently suffered a serious illness or infection. In these circumstances, diabetic control may not be achievable.

• If you are under 18or over 75 years old, Repaglinida Stada is not recommended. It has not been studied in these age groups.

If you have hypoglycemia

You may experience hypoglycemia (low blood sugar) if your blood sugar level is too low. This can occur if:

• You take too much Repaglinida Stada

• You engage in more physical exercise than usual

• You take other medications or have kidney or liver problems (see other sections of section 2, What you need to know before taking Repaglinida Stada).

Warning signs of hypoglycemiaappear suddenly and can include: cold sweat, cold and pale skin, headache, palpitations, nausea, excessive hunger, temporary visual disturbances, fatigue, unusual weakness and tiredness, nervousness or tremors, anxiety, confusion, and difficulty concentrating.

If your blood sugar level is low or if you feel you are going to have hypoglycemia:take glucose tablets or a sugary product or drink, and then rest.

When the symptoms of hypoglycemia disappear or when blood sugar levels stabilize, continue treatment with Repaglinida Stada.

Tell others that you are diabeticand if you lose consciousnessdue to hypoglycemia, they should lay you on your side and seek immediate medical attention. They should not give you anything to eat or drink, as you may choke.

• If severe hypoglycemiais not treated, it can cause brain damage (temporary or permanent) and even death.
• If you experience hypoglycemiathat causes you to lose consciousness or if you have repeated hypoglycemic episodes, inform your doctor. You may need to adjust the dose or administration schedule of Repaglinida Stada, your diet, or exercise.

If your blood sugar level is too high

Your blood sugar level may be too high (hyperglycemia). This can occur:

• If you take too little Repaglinida Stada

• If you have an infection or fever

• If you eat more than usual
• If you engage in less physical exercise than usual.

Warning signsappear gradually. These include: excessive urination, thirst, dry skin, and a feeling of dryness in the mouth. Inform your doctor. You may need to adjust the dose of Repaglinida Stada, your diet, or exercise.

Other medications and Repaglinida Stada

Tell your doctor or pharmacist if you are taking, have recently taken, or may take any other medications.

If your doctor prescribes it, you can take Repaglinida Stada with metformin, another diabetes medication. If you take gemfibrozil (used to lower blood fat levels), you should not take Repaglinida Stada.

Your body's response to Repaglinida Stada may change if you take other medications, especially:

• Monoamine oxidase inhibitors (MAOIs) (for the treatment of depression)
• Beta-blockers (for the treatment of high blood pressure or heart disease)

• Angiotensin-converting enzyme (ACE) inhibitors (for the treatment of heart disease)
• Salicylates (e.g., aspirin)

• Octreotide (for the treatment of cancer)
• Non-steroidal anti-inflammatory drugs (NSAIDs) (a type of pain reliever)
• Steroids (anabolic steroids and corticosteroids, for anemia or to treat inflammation)
• Oral contraceptives (to prevent pregnancy)

• Thiazides (diuretics)
• Danazol (for the treatment of breast cysts and endometriosis)
• Thyroid products (for the treatment of low thyroid hormone levels)

• Sympathomimetics (for the treatment of asthma)
• Clarithromycin, trimethoprim, rifampicin (antibiotic medications)

• Itraconazole, ketoconazole (medications for fungal infections)
• Gemfibrozil (to treat high blood fat levels)
• Cyclosporin (to suppress the immune system)
• Deferasirox (to reduce chronic iron overload)
• Clopidogrel (to prevent blood clots)

• Phenytoin, carbamazepine, phenobarbital (for the treatment of epilepsy)
• St. John's Wort (herbal medicinal plant)

Using Repaglinida Stada with food, drinks, and alcohol

Take Repaglinida Stada before main meals. Alcohol can alter Repaglinida Stada's ability to lower blood sugar levels. Be aware of the symptoms of hypoglycemia.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

Do not take Repaglinida Stada if you are pregnant or plan to become pregnant. Consult your doctor as soon as possible if you become pregnant or plan to become pregnant during treatment.

Do not take Repaglinida Stada if you are breastfeeding.

Driving and using machines

Your ability to drive or operate machinery may be affected if your blood sugar level is low or high. Be aware that you may put yourself or others at risk. Consult your doctor about the possibility of driving a car if:

• You have frequent hypoglycemic episodes

• You have few or no symptoms of hypoglycemia

Repaglinida Stada contains sodium

This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".

3. How to take Repaglinida Stada

Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Your doctor will calculate your dose.

• The recommended initial doseis 0.5 mg taken just before each main meal. The tablets should be taken with a glass of water just before or within 30 minutes before each main meal.

• The dose may be adjusted by your doctor up to 4 mg, which should be taken just before or within 30 minutes before each main meal. The maximum recommended dose is 16 mg per day.

Do not take more Repaglinida Stada than your doctor has recommended.

If you take more Repaglinida Stada than you should

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 5620420, indicating the medication and the amount ingested.

If you take too many tablets, your blood sugar level may become too low and cause hypoglycemia. Please read what hypoglycemia is and how to treat it in the section If you have hypoglycemia.

If you forget to take Repaglinida Stada

If you forget to take a dose, take the next dose as you normally would. Do not take a double dose to make up for forgotten doses.

If you stop taking Repaglinida Stada

Be aware that the desired effect will not be achieved if you stop taking Repaglinida Stada. Your diabetes may worsen. If any change in your treatment is necessary, consult your doctor first.

If you have any further questions about the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medications, this medication can have side effects, although not everyone will experience them.

Common (may affect up to 1 in 10 people)

• Hypoglycemia (see the section If you have hypoglycemiain section 2 of the package leaflet). The risk of hypoglycemia may increase if you take other medications.
• Stomach pain.
• Diarrhea.

Rare (may affect up to 1 in 1,000 people)

• Acute coronary syndrome (but may not be due to the medication)

Very rare (may affect up to 1 in 10,000 people)

• Allergic reaction (such as swelling, difficulty breathing, palpitations, symptoms of dizziness, and sweating that may be symptoms of an anaphylactic reaction). Consult your doctor immediately.

• Vomiting.
• Constipation.
• Visual disturbances.

• Serious liver problems, abnormal liver function, and increased liver enzymes in the blood.

Frequency not known(frequency cannot be estimated from available data)

• Hypoglycemic coma or loss of consciousness (very severe hypoglycemic reactions, see the section If you have hypoglycemia). Contact your doctor immediately.
• Hypersensitivity (such as rash, itching, redness, and swelling).

• Feeling unwell (nausea)

Reporting side effects

If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them through the Spanish Medicines Agency's online system. https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.

5. Storage of Repaglinida Stada

Keep this medication out of the sight and reach of children.

No special storage conditions are required.

Do not use Repaglinida Stada after the expiration date stated on the packaging, after EXP. The expiration date is the last day of the month indicated.

Medications should not be disposed of through wastewater or household waste. Deposit the packaging and any unused medications in the pharmacy's SIGRE collection point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medications. This will help protect the environment.

6. Package contents and additional information

Composition of Repaglinida Stada

The active ingredient is repaglinide. Each tablet contains 1 mg of repaglinide.

The other ingredients are: microcrystalline cellulose, poloxamer 188, sodium croscarmellose, and magnesium stearate.

Appearance of the product and package contents

Repaglinida Stada 1 mg are white, round, 3.4 mm thick, biconvex tablets with a "1" embossed on them.

Repaglinida Stada is available in packages containing 15, 30, 90, 120, 180, or 270 tablets.

Not all package sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder

Laboratorio STADA, S.L.

Frederic Mompou, 5

08960 Sant Just Desvern

(Barcelona)

[email protected]

Manufacturer

STADA Arzneimittel AG,

Stadastr. 2-18,

D-61118 Bad Vilbel,

Germany

or

Stada Arzneimittel GmbH,

Muthgasse 36,

1190 Wien,

Austria

or

Eurogenerics N.V.,

Heizel Esplanade B22,

B-1020 Brussels,

Belgium

or

LAMP SAN PROSPERO S.p.A.,

Via della Pace, 25/A,

41030 San Prospero (Modena),

Italy

This medication is authorized in the Member States of the European Economic Area under the following names:

AT: Repaglinid Stada 1 mg - Tabletten

BE: Repaglinide EG 1mg tabletten

BG: Indorin 1 mg tablets

DE: Repaglinid STADA 1 mg Tabletten

ES: Repaglinida STADA 1 mg comprimidos EFG

FI: Repaglinid STADA 1 mg tabletti

FR: REPAGLINIDE EG 1 mg, comprimé

IT: REPAGLINIDE EG 1 mg compresse

LU: Repaglinide EG 1 mg comprimés

RO: Repaglinida HF 1 mg comprimate

SI: Repaglinid STADA HEMOFARM 1 mg tablete

SE: Repaglinid STADA 1 mg tabletter

NL: Repaglinide STADA 1 mg, tabletten

Date of the last revision of this package leaflet:May 2023

Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/